Vestibular & Vertigo Tablets (Betahistine‑based)
For Healthcare Professionals & Licensed DistributorsBetahistine dihydrochloride tablets are used by neurologists, ENT specialists, and other HCPs for the management of vertigo‑related symptoms in patients with vestibular disorders. This page is for clinicians and licensed distributors seeking category‑level information and potential PCD‑style distribution support, not for direct‑to‑consumer sale.
Clinical use in vestibular disorders
Bilastine is a selective peripheral H1‑receptor antagonist used for:- Betahistine‑based tablets are indicated for symptomatic relief in patients with vestibular vertigo, including Ménière‑type symptoms and chronic positional vertigo.
- Observational studies suggest that betahistine (typically 48 mg/day in divided doses) can reduce vertigo attack frequency, decrease severity, and improve associated symptoms such as nausea and vomiting.
Formulation and dosing profile
- Betahistine dihydrochloride is commonly available as 8 mg and 16 mg tablets, usually prescribed in multiple daily doses (e.g., 8 mg three times daily) under specialist supervision.
- The drug is generally well tolerated, though dose‑adjustment or discontinuation may be considered in patients with peptic ulcer disease or hypersensitivity.
For HCPs & licence‑holding distributors
- This information is intended for neurologists, ENT specialists, and drug‑distributors who manage availability in hospitals, clinics, and specialty pharmacies.
- Medicines should be supplied to legally registered entities only, in compliance with local pharmacy and medical regulations.
